This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Galiè, N. Articles by Rubin, L. Search for Related Content PubMed PubMed Citation Articles by Galiè, N. Articles by Rubin, L.

Effects of the oral endothelin-receptorantagonist bosentan on echocardiographicand doppler measures in patients with pulmonary arterial hypertension

Nazzareno Galiè, MD^*,*, Alan L. Hinderliter, MD, Adam Torbicki, MD, Thierry Fourme, MD, Gerald Simonneau, MD, Tomas Pulido, MD^||, Nilda Espinola-Zavaleta, MD^||, Guido Rocchi, MD^*, Alessandra Manes, MD^*, Robert Frantz, MD^¶, Marcin Kurzyna, MD, Sherif F. Nagueh, MD^#, Robyn Barst, MD^**, Richard Channick, MD, Karl Dujardin, MD, Andrew Kronenberg, MD, Isabelle Leconte, PhD, Maurizio Rainisio, PhD and Lewis Rubin, MD

^* Institute of Cardiology, University of Bologna, Italy
Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA
Department of Chest Medicine, Institute of Tuberculosis and Lung Disease, Warsaw, Poland
Division of Pulmonary and Critical Care Medicine, University of Paris-Sud, Paris, France
^|| Instituto Nacional de Cardiologia, Mexico City, Mexico
^¶ Department of Cardiology, Mayo Clinic, Rochester, Minnesota, USA
^# Baylor College of Medicine and the Methodist Hospital, Houston, Texas, USA
^** Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York, New York, USA
Division of Pulmonary and Critical Care Medicine, University of California, San Diego, California, USA
Department of Cardiology, Gasthuisberg University Hospital, Leuven, Belgium
Actelion Ltd., Allschwil, Switzerland

View larger version (14K): [in a new window]   Figure 1 Change and standard error of the mean from baseline to week 16 in right ventricle to left ventricle (RV:LV) diastolic areas ratio in bosentan- and placebo-treated patients. The treatment effect was statistically significant for combined dose group (p = 0.007) and for 125 mg (p = 0.015) and 250 mg dose subgroups (p = 0.026). Black bar = bosentan; white bar = placebo.

View larger version (14K): [in a new window]   Figure 2 Change and standard error of the mean from baseline to week 16 in Doppler-derived cardiac index (CI) in bosentan- and placebo-treated patients. The treatment effect was statistically significant for combined dose group (p = 0.007) and for 125 mg (p = 0.019) and 250 mg dose subgroups (p = 0.020). Black bar = bosentan; white bar = placebo.

View larger version (14K): [in a new window]   Figure 3 Change and standard error of the mean from baseline to week 16 in Doppler right ventricle (RV) index in bosentan- and placebo-treated patients. The treatment effect was statistically significant for the combined treatment group (p = 0.034) and of borderline statistical significance for both 125 mg (p = 0.074) and 250 mg (p = 0.070) dose subgroups. Black bar = bosentan; white bar = placebo.